# Roivant Sciences

Type: Company (ROIV)

Source: GetYourBrief — https://getyourbrief.com/entity/roivant-sciences
Canonical HTML page: https://getyourbrief.com/entity/roivant-sciences

## Timeline

- **2026-03**: Settlement Reached — Moderna agrees to pay up to $2.25 billion to resolve all outstanding claims.
- **2024-04**: Claims Construction — Court rulings on patent definitions provide momentum for the plaintiffs.
- **2022-02**: Lawsuit Filed — Arbutus and Genevant sue Moderna for patent infringement in Delaware federal court.
- **2020-12**: Vaccine Launch — Moderna receives EUA for Spikevax, utilizing LNP technology for delivery.

## Recent coverage (2 stories, network-wide)

### Moderna to Pay Roivant $2.25 Billion to Settle mRNA Patent Litigation
2026-03-04 14:38:59 · Sector: bio · Sentiment: Neutral · Impact: 7/10 · Sources: 2

Moderna has reached a landmark $2.25 billion settlement with Roivant Sciences and Arbutus Biopharma to resolve long-standing patent disputes over lipid nanoparticle technology used in its COVID-19 vaccine. The agreement provides a massive capital infusion for Roivant while removing a significant legal overhang for Moderna's future mRNA pipeline.
Full story: https://getbiobrief.com/story/moderna-roivant-mrna-patent-settlement

### Moderna Settles mRNA Patent Dispute with Roivant for Up to $2.25 Billion
2026-03-04 14:38:26 · Sector: health · Sentiment: Neutral · Impact: 7/10 · Sources: 2

Moderna has agreed to pay Roivant Sciences up to $2.25 billion to settle long-standing patent infringement claims regarding the Lipid Nanoparticle (LNP) technology used in its COVID-19 vaccine. The settlement provides a massive capital windfall for Roivant and Arbutus Biopharma while removing a major legal risk for Moderna.
Full story: https://gethealthbrief.com/story/moderna-roivant-mrna-patent-settlement

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.